![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » California Finds Drugmakers Increased List Prices Way Above Inflation
California Finds Drugmakers Increased List Prices Way Above Inflation
![](https://www.fdanews.com/ext/resources/test/Drug-Images2/too-pricey.gif?t=1433864925&width=683)
October 7, 2019
Drugmakers increased the list prices of their drugs far beyond the inflation rate between 2017 and the first quarter of 2019, California found in a first-of-its kind study of 1,020 drugs based on the state’s mandatory wholesale price reporting requirements.
The average increase in the wholesale acquisition cost — the manufacturers’ list prices for wholesalers or direct purchasers — was 25.8 percent between 2017 and Q1 2019, according to the Office of Statewide Health Planning and Development.
The least expensive prescription drugs, priced at under $100, experienced the largest three-year increase of 37.6 percent. The annual inflation rate over the same period was two percent.
Upcoming Events
-
21Oct